Omeprazole and ketoconazole interaction in horses
Published: · Updated:
An official horse omeprazole label states that omeprazole may decrease absorption of drugs requiring an acidic gastric environment, including ketoconazole.
Summary references: [1]
Can omeprazole reduce ketoconazole absorption in horses?
The Omepratex horse product information says that omeprazole may decrease absorption of medicines requiring a lower gastric pH for optimal absorption, and names ketoconazole. The warning is about absorption; it is not evidence that every treated horse will have treatment failure. [1]
Mechanism and evidence interpretation
Reduced absorption at higher gastric pH. This is an official-label absorption warning for horses. It does not quantify ketoconazole exposure for a particular formulation, dose, route or patient. [1]
Omeprazole may decrease absorption of drugs requiring decreased gastric pH for optimal absorption (ketoconazole, itraconazole, iron, ampicillin esters). [1] [2] [3] [4] [5]
The quotation is the recorded official-label wording. It may mention other medicines; only the pair in this article’s title is discussed here.
Does separating administration times solve the interaction?
These are questions for veterinary review, not instructions to start, stop or change a medicine.
- The cited warning does not establish a reliable spacing interval or a dose correction for this combination.
- Have the veterinarian check the exact ketoconazole formulation, route and treatment purpose before deciding how relevant the absorption warning is.
- Review the current horse omeprazole label and other medicines before changing a treatment plan.
Which animals and evidence types does this cover?
The selected catalogue scope is horses. A product-label statement is not automatically a controlled interaction trial. It does not establish an effect size, incidence, dose adjustment or applicability to another species.
Does a horse product label establish an interaction in every animal species?
No. This page concerns a statement in horse product information. It should not be silently transferred to dogs, reptiles or another target species, and it does not replace formulation-specific evidence.
No matching rule does not establish safety. FDA adverse-event reports alone cannot prove an interaction or its incidence.
Catalogue review status and limitations
The matched catalogue records are marked verified and direct. This is a catalogue review status; it does not mean every patient-specific conclusion has been clinically demonstrated.
- Catalogue review status
- verified
- Inference status
- direct
- Stored interaction role
- risk_interaction
- Catalogue severity
- moderate
These fields are shown separately. They are not a claim of independent expert consensus or a patient-specific recommendation.
Evidence sources
This page draws on 5 catalogue record(s) and 5 distinct source entries. These are not independent clinical studies; repeated product labels may carry the same warning.
The summary was checked against the linked primary VMD PDF on 16 November 2026. Source URLs can change; the catalogue citations retain recorded version identifiers.
- Official product information
VMD PID:A013451, Omepratex 370 mg/g Oral Paste for Horses, version 56370555dd50ca2a78ee2c233a718461 Open official source
- Official product information
VMD PID:A013447, Gastazole 370 mg/g Oral Paste for Horses, version 0c18ac813e85d4901fb997157f704639 Open official source
- Official product information
VMD PID:A013453, EU Pharma Omeprazole 370 mg/g Oral Paste for Horses, version c4f2ebc90fd20707cbc626a9c3e8c807 Open official source
- Official product information
VMD PID:A013448, Omeprogard 370 mg/g Oral Paste for Horses, version 9b56cd113769235b96635e4c6f927ce3 Open official source
- Official product information
VMD PID:A013450, Omepratex 370 mg/g Oral Paste for Horses, version b75d97ecabe87f85976f33d55b6d6078 Open official source
Content responsibility: ZooDDI. This is a source-linked reference for veterinary review, not a diagnosis, prescription or emergency service. No independent clinical reviewer is claimed.